Two types of amyloidosis presenting in a single patient: a case series

M. Hasib Sidiqi, Ellen McPhail, Jason D. Theis, Surendra Dasari, Julie A. Vrana, Maria Eleni Drosou, Nelson Leung, Suzanne Hayman, S Vincent Rajkumar, Rahma Warsame, Stephen Maxted Ansell, Morie Gertz, Martha Grogan, Angela Dispenzieri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. The most common types were transthyrethin (n = 9) and immunoglobulin-derived (n = 7). Two patients did not have immunoglobulin-derived amyloidosis despite the presence of a monoclonal gammopathy. Eight patients were diagnosed with two types concurrently, and one patient had an 11-year interval between diagnoses. Histopathological distribution of amyloid was variable with vascular, interstitial, and periosteal deposits seen. Identification of a second type was incidental in seven patients, but led to genetic counselling in one patient and therapy directed at both amyloid subtypes in another. With longer survival of myeloma and AL amyloidosis patients and increasing prevalence of patients with wild-type transthyretin amyloidosis due to an aging population, the phenomenon of two amyloid types in a single patient will be encountered more frequently. In light of revolutionary new therapies for transthyretin amyloidosis (patisiran, tafamidis, and inotersen), recognition of dual amyloid types is highly clinically relevant.

Original languageEnglish (US)
Article number30
JournalBlood cancer journal
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Amyloidosis
Amyloid
Immunoglobulins
Amyloidogenic Proteins
Paraproteinemias
Genetic Counseling
Tandem Mass Spectrometry
Liquid Chromatography
Blood Vessels
Therapeutics
Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Two types of amyloidosis presenting in a single patient : a case series. / Sidiqi, M. Hasib; McPhail, Ellen; Theis, Jason D.; Dasari, Surendra; Vrana, Julie A.; Drosou, Maria Eleni; Leung, Nelson; Hayman, Suzanne; Rajkumar, S Vincent; Warsame, Rahma; Ansell, Stephen Maxted; Gertz, Morie; Grogan, Martha; Dispenzieri, Angela.

In: Blood cancer journal, Vol. 9, No. 3, 30, 01.03.2019.

Research output: Contribution to journalArticle

Sidiqi, M. Hasib ; McPhail, Ellen ; Theis, Jason D. ; Dasari, Surendra ; Vrana, Julie A. ; Drosou, Maria Eleni ; Leung, Nelson ; Hayman, Suzanne ; Rajkumar, S Vincent ; Warsame, Rahma ; Ansell, Stephen Maxted ; Gertz, Morie ; Grogan, Martha ; Dispenzieri, Angela. / Two types of amyloidosis presenting in a single patient : a case series. In: Blood cancer journal. 2019 ; Vol. 9, No. 3.
@article{818a4bd133bc4da2bc15fec34fb2bee4,
title = "Two types of amyloidosis presenting in a single patient: a case series",
abstract = "The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. The most common types were transthyrethin (n = 9) and immunoglobulin-derived (n = 7). Two patients did not have immunoglobulin-derived amyloidosis despite the presence of a monoclonal gammopathy. Eight patients were diagnosed with two types concurrently, and one patient had an 11-year interval between diagnoses. Histopathological distribution of amyloid was variable with vascular, interstitial, and periosteal deposits seen. Identification of a second type was incidental in seven patients, but led to genetic counselling in one patient and therapy directed at both amyloid subtypes in another. With longer survival of myeloma and AL amyloidosis patients and increasing prevalence of patients with wild-type transthyretin amyloidosis due to an aging population, the phenomenon of two amyloid types in a single patient will be encountered more frequently. In light of revolutionary new therapies for transthyretin amyloidosis (patisiran, tafamidis, and inotersen), recognition of dual amyloid types is highly clinically relevant.",
author = "Sidiqi, {M. Hasib} and Ellen McPhail and Theis, {Jason D.} and Surendra Dasari and Vrana, {Julie A.} and Drosou, {Maria Eleni} and Nelson Leung and Suzanne Hayman and Rajkumar, {S Vincent} and Rahma Warsame and Ansell, {Stephen Maxted} and Morie Gertz and Martha Grogan and Angela Dispenzieri",
year = "2019",
month = "3",
day = "1",
doi = "10.1038/s41408-019-0193-9",
language = "English (US)",
volume = "9",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Two types of amyloidosis presenting in a single patient

T2 - a case series

AU - Sidiqi, M. Hasib

AU - McPhail, Ellen

AU - Theis, Jason D.

AU - Dasari, Surendra

AU - Vrana, Julie A.

AU - Drosou, Maria Eleni

AU - Leung, Nelson

AU - Hayman, Suzanne

AU - Rajkumar, S Vincent

AU - Warsame, Rahma

AU - Ansell, Stephen Maxted

AU - Gertz, Morie

AU - Grogan, Martha

AU - Dispenzieri, Angela

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. The most common types were transthyrethin (n = 9) and immunoglobulin-derived (n = 7). Two patients did not have immunoglobulin-derived amyloidosis despite the presence of a monoclonal gammopathy. Eight patients were diagnosed with two types concurrently, and one patient had an 11-year interval between diagnoses. Histopathological distribution of amyloid was variable with vascular, interstitial, and periosteal deposits seen. Identification of a second type was incidental in seven patients, but led to genetic counselling in one patient and therapy directed at both amyloid subtypes in another. With longer survival of myeloma and AL amyloidosis patients and increasing prevalence of patients with wild-type transthyretin amyloidosis due to an aging population, the phenomenon of two amyloid types in a single patient will be encountered more frequently. In light of revolutionary new therapies for transthyretin amyloidosis (patisiran, tafamidis, and inotersen), recognition of dual amyloid types is highly clinically relevant.

AB - The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. The most common types were transthyrethin (n = 9) and immunoglobulin-derived (n = 7). Two patients did not have immunoglobulin-derived amyloidosis despite the presence of a monoclonal gammopathy. Eight patients were diagnosed with two types concurrently, and one patient had an 11-year interval between diagnoses. Histopathological distribution of amyloid was variable with vascular, interstitial, and periosteal deposits seen. Identification of a second type was incidental in seven patients, but led to genetic counselling in one patient and therapy directed at both amyloid subtypes in another. With longer survival of myeloma and AL amyloidosis patients and increasing prevalence of patients with wild-type transthyretin amyloidosis due to an aging population, the phenomenon of two amyloid types in a single patient will be encountered more frequently. In light of revolutionary new therapies for transthyretin amyloidosis (patisiran, tafamidis, and inotersen), recognition of dual amyloid types is highly clinically relevant.

UR - http://www.scopus.com/inward/record.url?scp=85062504234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062504234&partnerID=8YFLogxK

U2 - 10.1038/s41408-019-0193-9

DO - 10.1038/s41408-019-0193-9

M3 - Article

C2 - 30837451

AN - SCOPUS:85062504234

VL - 9

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 3

M1 - 30

ER -